Back

Qualifying event proximity, cardiovascular risk, and benefit of empagliflozin in patients with type 2 diabetes and stable atherosclerosis in the EMPA-REG OUTCOME trial

31 August 2019 (11:36 - 11:54)
Organised by:
Congress Presentation Part of: New frontiers: SGLT2 inhibitors in cardiorenal disease Antidiabetic Pharmacotherapy ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Jacob Allan Udell

University of Toronto, Toronto (Canada)

4 More presentations in this session

Presentation thumbnail
State of the Art - SGLT2 inhibitors in cardiovascular disease
Professor M. Sabatine (Boston, US)
Slides Video
Presentation thumbnail
Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58
Doctor T. Zelniker (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes
Doctor C. Noergaard (Aalborg, DK)
Abstract Slides Video
Presentation thumbnail
Integrating SGLT2 inhibitors in diabetes treatment: a guide for cardiologists
Professor N. Sattar (Glasgow, GB)
Slides Video

Access the full session

Session thumbnail
New frontiers: SGLT2 inhibitors in cardiorenal disease

The Event

Event poster

ESC Congress 2019

31 August 2019 11:36 CET
You may be interested in
thumbnail
Congress Presentation
Cardiovascular benefits of SGLT2i in type 2 diabetes without heart failure: a subgroup analysis
thumbnail
Congress Presentation
Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease, in high-risk type 2 diabetes
thumbnail
Congress Presentation
Efficacy and safety of dapagliflozin in non-diabetic patients with anterior wall ST-segment elevation acute myocardial infarction

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources